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Abstract 
The introduction of NBS in ROI in July 2011 provided a unique opportunity to 
investigate clinical outcomes using a comparative historical cohort study. Clinical 
cohort: children clinically diagnosed with CF born 01/07/2008-30/06/2011, and NBS 
cohort: children diagnosed with CF through NBS born 01/07/2011-30/06/2016. 
Clinical data was collected from the CF Registry of Ireland, medical charts and data 
 











on weight/height prior to diagnosis from public health nurses and family doctors. 
SPSS was used for analysis. 
232 patients were recruited (response 93%) (93 clinically diagnosed, 139 NBS-
detected. Following exclusions of Meconium Ileus (MI) (40), diagnosis outside ROI 
(4) and being designated as CFSPID (2), a total of 77 clinically diagnosed patients 
and 109 NBS detected children were included in analysis. Over half were 
homozygous for F508del mutation. Being clinically diagnosed was independently 
associated with hospitalisation for infective exacerbation of CF < 36 months (OR 
2.80; 95%CI 1.24-6.29). Diagnosis to first acquisition of P. aeruginosa was 
significantly longer in NBS than clinically detected; from birth there was no 
significant difference. Weight and length/height were significantly greater in NBS 
cohort at 6 and 12 months. 
We provide evidence of improved growth, reduced hospitalisation for acute 
exacerbations and delayed P. aeruginosa acquisition (from diagnosis) to age 3 for the 
NBS cohort. Screening practices likely account for the non-significant difference in P. 
aeruginosa acquisition from birth. 
Introduction 
From the outset of CF screening concerns have been raised as to whether there was 
sufficient evidence that screened infants would benefit from their earlier diagnosis1-3. 
Only two clinical trials of CF newborn screening (NBS) have been performed, with 
early results far from compelling4,5. A wealth of evidence has subsequently been 
accrued that demonstrate the benefits of CF NBS across a host of outcomes6-10. Since 
the initial studies two major changes in CF care have evolved, namely the 
development of CF specialist centres, and the instigation of strict infection control 
guidelines11,12. There remains a requirement to continue to assess the potential 
benefits, and harms, of CF NBS programmes in the era of modern CF care1,6,13. The 
introduction of NBS in the Republic of Ireland in July 2011 provided a unique 
 











opportunity to investigate the clinical outcomes of two cohorts of children (NBS vs. 
clinical cohort).  
The Republic of Ireland has one of the highest reported incidences of CF in the world 
(1/1353) with an estimated carrier rate of approximately 1 in 20 14. It was feasible to 
study the whole population of children born during this time period as a single 
screening programme was introduced nationally, and CF is a rare disease with 
approximately 25 to 30 infants presenting with CF through NBS in Ireland each year 
15. Children that are diagnosed both clinically and through NBS are only referred to 
one of the six specialist paediatric CF centres in Ireland with geographically defined 
catchment areas. All centres have full CF multi-disciplinary teams, with strict 
infection control policies in place. Patients attend the centres frequently in the initial 
months, at the discretion of the treating consultant, until established on standard CF 
care and are stable. They are then seen three monthly and for annual review at one of 
the specialist centres, which are located in the capital city Dublin (3 centres) and in 3 
other large cities. Once diagnosed with CF all children receive long term illness 
benefit and/or a medical card, which allows free GP, outpatient and inpatient hospital 
care. 
In 2016 the population was 4.76 million in April 2016, an increase of 173,613 (3.8%) 
since April 2011; 39% of the total urban population live in Dublin, while 9% live in 
Cork, the second largest city and37.3% of the total population live in rural areas 16.  
Methods 
This was a national historical cohort study that followed two cohorts of children with 
a diagnosis of CF:  
 











• Cohort A; clinical cohort: children clinically diagnosed with cystic fibrosis born 
in the Republic of Ireland between 1st July 2008 and 30th June 2011. 
• Cohort B; NBS cohort: children diagnosed with cystic fibrosis through NBS 
born in the Republic of Ireland between 1st July 2011 and 30th June 2016.  
Children designated as Cystic Fibrosis Screen Positive, Inconclusive Diagnosis 
(CFSPID) were excluded from the study. Children born outside the ROI but receiving 
care at the specialist centres were also excluded as the aim of this study was to 
evaluate the Irish CF NBS programme. Children presenting with meconium ileus (MI) 
were excluded from analysis, to allow comparison with other studies that excluded 
MI 5.  
Learning from the experience of the French group 17, Ireland elected not to include 
R117H in our 38 CF mutation panel in tier 2 of the screening programme. That said, if 
a child has an equivocal sweat test value, and/or sweat chloride value > 60 mmol/L 
with one CF causing variant identified, then R117H is included in the extended gene 
analysis. With this approach, none of the children identified with R117H variant were 
diagnosed as classic CF but have been designated as CFSPID. As children with CFSPID 
do not have CF, we have not included this cohort in our study. 
The clinicians and CF nurses at the six specialist centres obtained informed consent 
from parents of eligible children to participate in the study when they attended for 
their routine clinic appointment at their designated centres. Recruitment began in July 
2014 and was completed by October 2016. Clinical data on patients was collect from 
three sources: the Cystic Fibrosis Registry of Ireland (CFRI)18, medical chart review 
and data on weight and height prior to diagnosis from children’s public health nurses 
and family doctors.  
 











To monitor the normal growth and development of children with CF in Ireland weight 
and height are measured at each clinic visit. Data on weight and height at each time 
point included in the analysis was +/- 1 month, if there was no data on weight or 
height at this time point then these patients were excluded from the analysis. As there 
was a significant delay in diagnosing some children not screened for CF at birth, data 
on these children’s weight and height prior to diagnosis was not available from the 
patients’ medical chart. Therefore, data was sought on weight and height prior to 
diagnosis from the child’s general practitioner or public health nurse (PHN). In 
Ireland PHNs record weight, height and head circumference at birth, 3 months, 
between 7 and 9 months, between 18 and 24 months and between 3 to 3.5 years 
(weight and height only).  
Additional clinical data was collected from the patients’ medical chart, as not all 
patients were registered with the CFRI, there was often a lag time from when patients 
were recruited by the CFRI and data was collected and some data was missing from 
the CFRI. This allowed capture of additional data that was not collected by the CFRI. 
Hospitalisation for acute exacerbations of CF and P. aeruginosa culture was 
documented through chart review, parent questionnaire and CFRI data. 
Hospitalisation was compared in those >36 months only. Information on hospital 
admissions prior to diagnosis was not always recorded in the medical chart as these 
admissions may not have occurred at the specialist centre where the child 
subsequently received their CF care, so information on these admissions was collected 
through a parent questionnaire. Only hospital admissions that were considered to be 
associated with a CF related problem e.g. admissions for any respiratory problems, 
gastrointestinal problems (failure to thrive, rectal prolapse) were documented. If there 
was no indication for admission these hospital admissions were excluded. 
 











One patient in the NBS cohort was diagnosed when their younger sibling was 
detected via NBS; they had an initial false negative result on the NBS at birth (age at 
diagnosis was 25.4 months). This patient was included in the analysis. 
Logistic regression was used to determine factors independently associated with ≥1 
hospital admission for pulmonary CF exacerbations only. An independent t test was 
for comparison of growth parameters. Kaplan Meier graphs and log rank test were 
used for comparison of time to P. aeruginosa acquisition from birth and from date of 
diagnosis. Multivariable adjusted Cox proportional hazards regression model was 
used to analyse the effect of clinical and demographic factors on time to first P. 
aeruginosa infection. SPSS version 20 was used to analyse the data. A p-value of < 
0.05 was deemed statistically significant. Ethical approval was received from each of 
the six specialist CF centres. 
Results 
A total of 232 patients were recruited to the ICOS study, representing a participation 
rate of almost 93%. Of the 93 clinically diagnosed children one patient was excluded 
due to being diagnosed outside the ROI. 15 patients were diagnosed due to 
presentation with meconium ileus; as these patients follow a different clinical course 
they were excluded from the overall analysis. A total of 77 clinically diagnosed 
patients were included in the final analysis. Of the 139 children diagnosed as a result 
of NBS five were excluded, due to diagnosis outside ROI (n=3) and being designated 
as CFSPID (n=2); there were 25 MI patients excluded from the overall analysis, 
leaving 109 children detected through NBS for analysis. The majority of children in 
the NBS cohort had their first clinical visit with a paediatric specialist within 21 days 
 











of life; intervention and treatment for CF commenced immediately once the diagnosis 
was confirmed. 
The demographic and clinical characteristics are presented in Table 1. The NBS 
cohort had a significantly earlier age at diagnosis than the clinical cohort (0.69 vs. 
10.22 months p=0.001). Over half the children in both cohorts were homozygous for 
the F508del mutation (NBS cohort 52.3%; clinical cohort 59.7%). Over 50% of 
children were breastfed and over 40% had private health insurance (which was used 
as a marker for socio-demographic status).  
There was no significant difference between the two groups with regard to parental 
smoking, private health insurance, sex, breastfeeding, child living with both parents, 
CFTR mutations, pancreatic sufficiency and mother with a degree (Table 1). However 
significantly more children in the clinical cohort had a sibling with CF compared to 
the NBS cohort (27.4% vs 13.9%; p=0.024) and the clinical cohort were more likely 
to have a mother with Irish nationality (95.9% vs 86.1%; p=0.031). 
A significantly greater proportion of children in the clinically diagnosed group 55.8% 
(n= 43) had 1 or more hospital admissions compared with 34.5% (n=20) in the 
screened group (p <.05) in the first 36 months of life. As some clinically diagnosed 
children may have had multiple admissions prior to diagnosis, in the clinically 
diagnosed group hospital admissions before diagnosis with CF are included in 
analysis. Being clinically diagnosed was significantly associated with hospitalisation 
for infective exacerbation of CF in the first 36 months after adjusting for sex, sibling 
with CF and genotype (OR 2.80; 95% CI 1.24, 6.29) (Table 2).  
A total of 179 patients were included in the analysis comparing P. aeruginosa 
acquisition between the two cohorts (six children were excluded from the analysis as 
 











they were greater than 60 months at the time of diagnosis with CF). The median age 
at first P. aeruginosa acquisition from birth was 24.1 (IQR 13.0-36.5) months in the 
NBS cohort and 57.8 (IQR 27.3-60.0) months in the clinical cohort. The median age 
at first P. aeruginosa acquisition from date of diagnosis was 22.7 (IQR 11.7-35.0) 
months in the NBS cohort and 27.9 (IQR 13.0-53.4) months in the clinical cohort. 
There was no significant difference in time from birth to P. aeruginosa acquisition in 
the two groups (Figure 1) but time from diagnosis to first acquisition of P. aeruginosa 
was significantly longer in screen-detected children than clinically-detected (p<0.05) 
(Figure 2).  
Multivariable adjusted Cox proportional hazards regression model was used to 
analyse the effect of clinical and demographic factors on time to first P. aeruginosa 
infection. The model was adjusted for method of diagnosis (NBS, clinical), gender, 
genotype, having another sibling with CF, prophylactic antibiotics and hospital 
admissions for any CF related problem in the first 36 months of life. Those children 
that have a sibling with CF were more likely (adjusted hazard ratio, 2.49; 95% 
(CI;1.28-4.82) to acquire P. aeruginosa as were children that had ≥1 hospital 
admissions for any CF related problem in the first 36 months of life (adjusted hazard 
ratio, 2.74; 95% CI; 1.41-5.32). 
Mean weight (Kg) and weight-for-age-z-score, length and height-for-age-z-score were 
significantly greater in screen-detected children at age 6 and 12 months (Table 3). 
There was no difference seen between the two groups from 18 months. 
Discussion  
This study provides evidence of improved growth, reduced hospitalisation for acute 
exacerbation of CF and delayed P. aeruginosa acquisition (when examined from date 
 











of diagnosis) in the early years post diagnosis for the NBS cohort in comparison to the 
clinical cohort, demonstrating that there remain clear advantages to being diagnosed 
via CF NBS. 
These early marginal gains are important and are likely to have long term 
implications. There is a wealth of evidence that CF lung disease begins early in life 19-
26. There is also compelling evidence that early manifestation of CF have long lasting 
implications well into later life 27-29.  
This study confirms and extends prior findings that children with CF diagnosed 
clinically are more likely to be hospitalised in early life for pulmonary exacerbations 
compared to children diagnosed via NBS30. The number of hospital admissions 
associated with a pulmonary exacerbation was also significantly greater for the 
clinical cohort in the first 24 months of life; this may indicate that the clinical cohort 
had more severe symptoms requiring more aggressive and longer treatment. Byrnes et 
al demonstrated the rate of exacerbations in the first two years of life was associated 
with reduced lung function at five years of age 29. The importance of avoiding severe 
exacerbations requiring admission was demonstrated in the same study. The 
researchers demonstrated that ever having a hospital managed exacerbation was 
associated with a doubling of the risk of bronchiectasis, and lower weight for age z-
scores at five years of age 29. Factors associated with P. aeruginosa in this study 
included having a sibling with CF and having a hospital admission in the first 36 
months of life. In this study most cases of first P. aeruginosa acquisition occurred 
after the child’s first hospital admission; hospitals can be a major source of infection 
for hospitalised patients despite improvements in infection control 31. Jarad and Giles 
(2008) in a cross-sectional study of patients with CF found that infection with P. 
aeruginosa was associated with increased number of pulmonary exacerbations 32. 
 











Children with CF requiring hospital admission for pulmonary exacerbation in the first 
36 months may also be more likely to have more severe disease. Other studies have 
found that siblings are more likely to become colonised with P. aeruginosa earlier, 
particularly the younger child with CF within a family 33,34. 
Findings from the study demonstrate that the NBS cohort appears to acquire P. 
aeruginosa sooner compared to the clinical cohort. One reason for this may be that 
the NBS cohort are diagnosed earlier and have more respiratory surveillance 
following diagnosis. The median age of diagnosis for the clinical cohort is 10 months. 
As P. aeruginosa can be transient without respiratory surveillance it is difficult to say 
if the clinical cohort acquired P. aeruginosa prior to diagnosis. When time to first P. 
aeruginosa acquisition was examined from date of diagnosis there was a significant 
difference with the clinical cohort acquiring P. aeruginosa sooner once diagnosed 
compared with the NBS cohort. Once diagnosed the clinical cohort have regular 
respiratory surveillance.  
Findings from the study demonstrate that there was no significant difference in time 
to first P. aeruginosa between the two cohorts from birth. However, the NBS cohort 
appears to acquire P. aeruginosa sooner compared to the clinical cohort. Attendance 
at a CF specialist centre should result in increased surveillance for CF pathogens, 
which may result in increased pathogen detection, particularly of P. aeruginosa 11,29. 
A second potential risk for earlier acquisition of P. aeruginosa in screen infants 
attending a specialist CF centre is the use of prophylactic antibiotics largely targeted 
at early Staphylococcus aureus infection but coming with a risk of early P. aeruginosa 
acquisition 35. This initial concern with prophylactic antibiotics has not been borne 
out by subsequent studies however the issue remains unresolved 11,29. Despite 
 











frequent surveillance for airway infection, and prophylactic antibiotic use, children 
diagnosed via screening did not have P. aeruginosa detected at a younger age in our 
study. Strict infection control policies are likely to have contributed to later 
acquisition of P. aeruginosa from time of diagnosis in screened infants. With regular 
surveillance from diagnosis, the clinically diagnosed group acquire P. aeruginosa 
significantly sooner once they are diagnosed. 
In the cross-sectional analysis, improved growth for the NBS cohort was only seen in 
the first 12 months of life, while from 18 months upwards no difference was found 
between the two groups. The majority of clinically diagnosed children were diagnosed 
by 10 months and once children with CF are diagnosed treatment is commenced 
immediately. Pancreatic enzyme replacement therapy (PERT) is commenced if 
indicated and nutritional imbalances are corrected; this might have allowed the 
clinical cohort time to catch up with NBS cohort in relation to weight and height. As 
the NBS cohort age the sample size becomes smaller as many of the NBS cohort have 
not yet reached 60 months; this may have impacted on the ability to detect a 
significance difference. 
A historical cohort of children with CF has been followed for approximately 25 years 
in New South Wales, Australia. This study comprised two similar cohorts of children 
with CF as in the ICOS study, children diagnosed clinically with CF born three years 
prior to the commencement of screening for CF (July 1978 to July 1981) and those 
diagnosed through NBS for CF born 3 years after the introduction of NBS for CF 
(July 1981 to July 1984). Findings from this study were first published in 1998 36; 
similar results to the ICOS study were found at twelve months, with the NBS cohort 
significantly heavier than the clinical cohort. The Australian study did not find any 
 











significant difference in height between the two groups at 12 months, however a 
significant difference was found in relation to height at 12 months in the ICOS study. 
Waters et al 36 followed these two cohorts to ten years and found the NBS cohort to be 
significantly taller at 5 years and 10 years, but with no significant difference in weight 
found after 12 months. A subsequent study by McKay et al 8 that followed this cohort 
to 15 years found no difference in nutritional status, but the NBS cohort did have 
significantly better chest x-ray scores and lung function at 15 years compared with the 
clinical cohort. The most recent study following this cohort of children by Dijk et al 10 
found that the NBS cohort were significantly heavier and taller on transfer to adult 
care and were significantly less likely to have chronic P. aeruginosa infection, with 
lung function also significantly better. A survival difference was seen at 25 years 
between the two cohorts (25 deaths or lung transplants in the clinical cohort vs 13 in 
the NBS cohort, p=0.01). In the Wisconsin trial 5 weight and height were also 
improved in the screened group; height was most markedly improved until the group 
converged at between 10 to 12 years of age.  
Migration into Ireland grew steadily in the years 2000 to 2008; the most recent Irish 
Census 2016 16 shows a reduction of 1.6% of non-Irish nationals living in Ireland. The 
top non-Irish nationalities are Polish, UK, Lithuanian, Romanian, Latvian & 
Brazilian. Although there was no significant difference in the proportions of NBS 
detected and clinically diagnosed with homozygous F508del mutations, this may 
account for the non-significantly lower F508del frequency in the NBS group. 
One of the limitations of this study is the use of a non-contemporaneous cohort for 
comparison. For observational cohort studies it is preferable to select a 
contemporaneous cohort for comparison that, as far as possible, differs from the 
 











intervention cohort only by the intervention used (NBS for CF). For the ICOS study it 
was not possible to use a contemporaneous cohort as NBS for CF was introduced 
nationally in July 2011. To avoid chronology bias, it was decided to use historical 
controls from only the very recent past, therefore the shorter three-year (July 2008 to 
July 2011) timeframe was selected for the clinical cohort. Other studies evaluating 
clinical outcomes of children with CF have used a similar study design, for example 
the historical cohort of children with CF from New South Wales, Australia 36. To 
consider any bias that the use of historical controls may have introduced, any potential 
changes in clinical treatment of CF children in Ireland since 2008 were examined. The 
most marked change in CF care in the period has been the introduction of Ivacaftor; 
this treatment only became available in Ireland from March 2013 for patients six 
years of age and over, therefore it did not affect the cohort of patients for this study. 
The CFRI has reported an increase in the use of nebulized hypertonic saline in 
patients < 18yrs in Ireland since 2008 15. However, a randomised control trial by 
Rosenfeld et al. (2012) 37 concluded that among infants and children younger than 6 
years with CF, the use of inhaled hypertonic saline compared with isotonic saline did 
not reduce the rate of pulmonary exacerbations.  
This study was limited by the number of patients that could be recruited. The 
Republic of Ireland (RoI) has one of the highest reported incidences of CF in the 
world 14. However, despite this the total numbers of cases diagnosed with CF through 
NBS each year are relatively small, due to the population size in the Republic of 
Ireland (4.76 million) 16. According to the CFRI, 27 children were detected with CF 
via NBS in 2012 15, which was the first complete year when NBS for CF was 
achieved (the CF NBS programme commenced in July 2011). Therefore, to increase 
 











the sample size and have comparable numbers to compare in each age group (6, 12, 
18, 24 months) the five years post screening were selected.  
CF NBS results in early detection of infants with CF and provides the opportunity to 
initiate standard CF care before features of the disease become established 38. 
However, it has been shown that even in infants diagnosed through NBS there is 
evidence of early CF lung disease affection airway infection, inflammation, lung 
function and airway structure 19-26. The validity of NBS for CF is improved if there is 
a clear evidence base on which to base clinical care. Despite a relative lack of robust 
evidence for core aspects of early CF care, this study shows improved growth, 
reduced hospitalisation for acute exacerbation of CF and improved surveillance for P. 
aeruginosa. We are on the cusp of a new era of CFTR modulator therapy; CF NBS 
will offer the opportunity to initiate this treatment early in life39,40.  
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Table 1. Demographic and clinical characteristics of children in the ICOS study 
(excluding children diagnosed with meconium ileus) (n = 186) 
Variable NBS (n = 109) 
 
Clinical (n = 77) 
 
p value 
Age at Diagnosis (Months) Median 
(IQR) 
0.69 (0.66-0.79) 10.22 (2.74-31.54) 0.001b 
Age at Study Enrolment (Months) 
Median (IQR) 
16.62 (8.72-33.10) 66.20 (54.12-
74.35) 
0.001b 
Birth Weight (kilograms) Mean 
(SD) 
3.27 (0.53) 3.25 (0.49) 0.836a 
Gestation at Birth (weeks) Mean 
(SD) 








Sex     
 
Male  52 (52.3) 40 (51.9) 0.569 
 
Female  57 (47.7) 37 (48.1) 
CFTR mutation    
 
ΔF508 homozygous 57 (52.3) 46 (59.7) 0.314 
 Other 52 (47.7) 31 (40.3) 
Pancreatic Sufficient    
 Yes 7 (6.4) 3 (3.9) 0.380 
 No 91 (83.5) 72 (93.5) 
 Missing 11 (10.1) 2 (2.6)  
Prophylactic Antibiotics    
 Yes 84 (77.1) 49 (63.6) 
0.050  No 22 (20.2) 25 (32.5) 
 Missing 3 (2.7) 3 (3.9) 
Highest Educational Attainment 
(Mother)  
   
 












Degree/postgraduate  43 (41.0) 24 (33.3) 0.305 
 
Less than Degree  62 (59.0) 48 (66.7) 
Mother Smoker     
 
Yes  19 (17.6) 11 (15.3) 0.683 
 
No  89 (82.4) 61 (84.7) 
Father Smoker     
 
Yes  25 (23.6) 12 (17.4) 0.327 
 
No  81 (76.4) 57 (82.6) 
Private Health Insurance     
 
Yes  46 (42.6) 35 (48.6) 0.427 
 
No  62 (57.4) 37 (51.4) 
Breastfed     
 
Yes  54 (51.4) 39 (54.2) 0.720 
 
No  51 (48.6) 33 (45.8) 
Child living with parents    
 
Both Parents 96 (88.9) 60 (83.3) 0.283 
  Single Family 12 (11.1) 12 (16.7) 
Other Siblings with CF    
 Yes  15 (13.9) 20 (27.4) 0.024 
 No  93 (86.1) 53 (72.6) 
Mother’s Nationality Irish    
 Yes  93 (86.1) 70 (95.9) 0.031 
















Table 2 Univariate and multivariate associations with ≥1 hospital admission for 




OR 95% CI 
 
Multivariate (Adjusted) a 
OR 95% CI 
 
Clinically Diagnosed   
 Yes 2.56 (1.27-5.17)**  2.80 (1.24-6.29)*  
 No (RC) 1.0 1.0 
Male    
 Yes 1.52 (0.77-3.01)  1.43 (0.63-3.24)  
 No (RC) 1.0 1.0 
Sibling with CF   
 Yes 0.65 (0.27-1.53)  0.55 (0.21-1.48)  
 No (RC) 1.0 1.0 
Mother Smoker   
 Yes 1.34 (0.51-3.50)  0.78 (0.24-2.52)  
 No (RC) 1.0 1.0 
Father Smoker   
 Yes 1.27 (0.54-2.99)  2.52 (0.80-7.95)  
 No (RC) 1.0 1.0 
Private Health Insurance   
 Yes 0.99 (0.50-1.99)  1.54 (0.64-3.70)  
 











 No (RC) 1.0 1.0 
ΔF508 homozygous   
 Yes 1.75 (0.88-3.49)  2.33 (1.04-5.22)*  
 No (RC) 1.0 1.0 
Breastfed   
 Yes 1.57 (0.78-3.17)  1.85 (0.84-4.07)  
 No (RC) 1.0 1.0 
OR Odds Ratio, CI Confidence Interval, RC Reference Category, a All the variables 
listed were included in the multivariate model. 
* p<0 .05, ** p<0.01 
 
Table 3. Cross-sectional comparison of growth indices between NBS and Clinical 
Cohort 
 
Variable  6 Months  12 
Months 












Weight (kg)          
































Weight-for-age-z-score            
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Height-for-age-z-score            






















































Figure 2. Kaplan Meier graph showing time to first P. aeruginosa culture from date of 
diagnosis 
 
 
 
